REVIEW article
Front. Cardiovasc. Med.
Sec. Structural Interventional Cardiology
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1682714
Nordic consensus document on Evolut FX+ transcatheter aortic valve implantation: optimizing index implantation and longer-term outcomes
Provisionally accepted
Arif Azhar Khokhar1*
Mikko Savontaus2Ahmed Al-Ani3Christian Juhl Terkselsen4
Gintautas Bieliauskas1Annemieke van der Heijden5Azad Al-hasan Amin6Stefan James6Kristoffer Russell7
Ole De Backer1- 1Rigshospitalet, Copenhagen, Denmark
- 2Turku Bioscience Centre, Turku, Finland
- 3Oslo universitetssykehus Ulleval sykehus, Oslo, Norway
- 4Aarhus Universitetshospital Afdeling Hjertesygdomme, Aarhus, Denmark
- 5Medtronic Inc, Santa Rosa, United States
- 6Uppsala universitet Kardiologi, Uppsala, Sweden
- 7Oslo universitetssykehus Rikshospitalet, Oslo, Norway
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduc?on Transcatheter aorDc valve replacement (TAVI) is an established treatment strategy for paDents with severe symptomaDc aorDc stenosis (AS) (1,2). MulDple landmark randomised controlled trials have consistently demonstrated the safety and efficacy of the Corevalve/Evolut (Medtronic, MN, USA) transcatheter aorDc valve (TAV) plajorm to treat severe AS (3–5). Long-term follow-up studies have confirmed stable valve hemodynamics with low rates of structural valve deterioraDon (SVD), which compares favourably compared to other surgical and transcatheter aorDc bioprostheses (6–9). These data have supported the expansion of TAVI towards younger paDents with longer-life expectancy (10,11). For this growing cohort of paDents, the index valve implantaDon can significantly impact both the acute procedural result, as well as longer-term outcomes on valve durability, coronary access and redo-TAVI (12–14). Therefore, achieving an opDmal index valve implantaDon becomes an essenDal first step, for semng up an effecDve lifeDme management strategy in younger paDents. In this technical narraDve, we aimed to describe how the iteraDve changes in the latest-generaDon Evolut FX(+) TAV can be uDlised to achieve an opDmised index valve implantaDon.
Keywords: transcatheter aorDc valve replacement, newest generaDon technology, opDmized implantaDon technique, commissural alignment, Coronary access
Received: 09 Aug 2025; Accepted: 24 Sep 2025.
Copyright: © 2025 Khokhar, Savontaus, Al-Ani, Terkselsen, Bieliauskas, van der Heijden, Amin, James, Russell and De Backer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Arif Azhar Khokhar, arifkhokhar@doctors.org.uk
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.